Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance. Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings support the efficacy of atenolol in doses of 50 to 200 mg/day.

Detaljer

Författare
  • Bengt Edvardsson
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurologi
Originalspråkengelska
Artikelnummer479
TidskriftSpringerPlus
Volym2
UtgivningsnummerSep 22
StatusPublished - 2013
PublikationskategoriForskning
Peer review utfördJa

Nedladdningar

Ingen tillgänglig data